The worry was that fast weight loss costs bone. In 161 million records, semaglutide users broke fewer bones — which needs explaining, not just reporting.
One in five cases now occurs under 54, up from one in ten thirty years ago. Rectal bleeding under 50 raises the odds of diagnosis eightfold.
Cost-effective per patient, unaffordable in aggregate. When 40% of adults qualify, those two things stop being contradictory.
Three receptors instead of two. Around 30% weight loss in the first trial, 21–23% in patients with diabetes and heart disease — and that difference is expected.
Vaccinate first and the antibody response is stronger early. Treat first and the arthritis improves sooner. By 12 weeks the antibody gap closes.
Semaglutide started at the mouse equivalent of late middle age added about 100 days of life and improved memory, muscle and blood sugar. The animals were neither obese nor diabetic — which is what makes the result interesting.
Adding a coronary calcium score to the AHA’s PREVENT calculator barely moved overall accuracy across 6,000 adults. But in the borderline-risk zone, a high score meant roughly seven times the event rate of a zero.
The phase 3 LONESTAR trial tested a widely assumed strategy — radiate or resect what remains after checkpoint blockade — and found no survival benefit, not even in the oligometastatic patients it was supposed to help most.
A genomic study of long-lived bats found their secret may be an exceptionally vigilant immune system — and cells that would rather self-destruct than risk becoming cancerous. It is a fresh angle on one of biology’s enduring puzzles.
NICE has declined to recommend Gilead’s lenacapavir for HIV prevention, calling it poor value for money — a decision HIV charities call a missed opportunity to end new infections.
Scholar Rock’s Isembyld (apitegromab) attacks spinal muscular atrophy from a new direction — the muscle itself — and is designed to layer on top of the nerve-focused drugs that transformed the disease over the past decade.
Camizestrant missed its main goal in the broad first-line SERENA-4 study, cooling expectations for a blockbuster hopeful even as the same drug had just earned an FDA approval in a narrower, biomarker-defined group.